Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells

2009 ◽  
Vol 35 (6) ◽  
pp. 719-726 ◽  
Author(s):  
Meenakshi Malhotra ◽  
Arun Kulamarva ◽  
Safaa Sebak ◽  
Arghya Paul ◽  
Jasmine Bhathena ◽  
...  
2018 ◽  
Vol 24 (23) ◽  
pp. 2673-2677 ◽  
Author(s):  
Yoko Endo-Takahashi ◽  
Kazuo Maruyama ◽  
Yoichi Negishi

Background: RNA interference (RNAi)-based therapy has gained attention because of its potent genesilencing effect and high specificity. However, the efficient delivery of nucleic acids to the target site is a major challenge to the clinical implementation. Recently, ultrasound-mediated gene delivery systems have been developed and attracted interest due to its safety and site-specificity. By the combination with contrast agents, called microbubbles, not only the delivery effects but also the imaging effects are significantly enhanced. We developed lipid bubbles (LBs) entrapping an ultrasound contrast gas to enhance the efficacy of ultrasound-mediated delivery and imaging. In this review, we summarize ultrasound-mediated nucleic acid delivery systems and discuss the possibility of combining LBs and ultrasound for RNAi-based therapies. Methods: We prepared polyethylene glycol-modified liposomes and entrapped an echo-contrast gas within the liposomes. Small interfering RNA (siRNA) were transfected into cells and muscles using LBs and ultrasound. Moreover, we also developed nucleic acid-loaded LBs using cholesterol-conjugated siRNA or positively-charged lipid for an efficient systemic delivery of siRNA and microRNA. The usability of LBs for RNA delivery system was evaluated by the silencing effects of target genes and the therapeutic effects on ischemia hind limb. Results: A combination of LBs and therapeutic ultrasound was able to enhance the gene silencing effects by siRNA. Nucleic acid-loaded LBs were able to efficiently deliver siRNA or microRNA by systemic administration. A combination of LBs and diagnostic ultrasound also enhanced the imaging efficiency. Using a hindlimb ischemia mouse model, microRNA-loaded LBs could lead to increased angiogenic factors and improved blood flow. Conclusion: Ultrasound technology is widely used in clinical settings not only for diagnosis but also for therapy. Ultrasonic devices are being actively developed. Computer-controlled ultrasound systems can provide precise exposure to the target site. The combination of precise ultrasound exposure and LBs might be useful for target site-specific nucleic acids delivery, and holds potential to be developed into a beneficial therapeutic and diagnostic system for various diseases.


2013 ◽  
Vol 13 (12) ◽  
pp. 1671-1680 ◽  
Author(s):  
Abdulaziz Almalik ◽  
Philip J. Day ◽  
Nicola Tirelli

2016 ◽  
Vol 106 ◽  
pp. 3-26 ◽  
Author(s):  
Rong Ni ◽  
Junli Zhou ◽  
Naushad Hossain ◽  
Ying Chau

2016 ◽  
Vol 31 (1) ◽  
pp. 54-61
Author(s):  
Ayaka Okamoto ◽  
Tomohiro Asai ◽  
Naoto Oku

Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 583
Author(s):  
Prisca Boisguérin ◽  
Karidia Konate ◽  
Emilie Josse ◽  
Eric Vivès ◽  
Sébastien Deshayes

Gene therapy offers the possibility to skip, repair, or silence faulty genes or to stimulate the immune system to fight against disease by delivering therapeutic nucleic acids (NAs) to a patient. Compared to other drugs or protein treatments, NA-based therapies have the advantage of being a more universal approach to designing therapies because of the versatility of NA design. NAs (siRNA, pDNA, or mRNA) have great potential for therapeutic applications for an immense number of indications. However, the delivery of these exogenous NAs is still challenging and requires a specific delivery system. In this context, beside other non-viral vectors, cell-penetrating peptides (CPPs) gain more and more interest as delivery systems by forming a variety of nanocomplexes depending on the formulation conditions and the properties of the used CPPs/NAs. In this review, we attempt to cover the most important biophysical and biological aspects of non-viral peptide-based nanoparticles (PBNs) for therapeutic nucleic acid formulations as a delivery system. The most relevant peptides or peptide families forming PBNs in the presence of NAs described since 2015 will be presented. All these PBNs able to deliver NAs in vitro and in vivo have common features, which are characterized by defined formulation conditions in order to obtain PBNs from 60 nm to 150 nm with a homogeneous dispersity (PdI lower than 0.3) and a positive charge between +10 mV and +40 mV.


2012 ◽  
Vol 132 (12) ◽  
pp. 1383-1388 ◽  
Author(s):  
Yoichi Negishi ◽  
Nobuhito Hamano ◽  
Hitomi Shiono ◽  
Saki Akiyama ◽  
Yoko Endo-Takahashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document